AsianScientist (Dec. 24, 2012) – MRC Technology has entered into a strategic drug discovery collaboration with the Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences (CAS).
The collaboration opens the U.K.-based technology transfer charity and company – whose focus is to fast track innovative drugable targets to create potent and selective novel therapeutics – up to a new source of drug targets from SIBCB researchers.
The agreement will combine the SIBCB’s research expertise in generating potential new drug targets with MRC Technology’s experience in further developing early stage research for pharmaceutical application and commercialization.
The collaboration was formalized at a signing ceremony held in Shanghai and attended by the senior management from both organizations including Dave Tapolczay and Michael Dalrymple (CEO and Director of Business Development, MRC Technology) and Professors Naihe Jing, Zhengjun Chen and Ge Jiang (Executive Director, Assistant Director, and Head of Science and Technology respectively, SIBCB).
“SIBCB is one of the world’s leading academic research institutions and the initiative reflects our joint commitment to delivering drugs for the treatment of diseases of global significance. The collaboration gives us a strong partner in China and access to potential new targets to further develop into drug therapies,” said Dave Tapolczay, CEO of MRC Techology.
——
Source: MRC Technology; Photo: Sanofi Pasteur/Flickr/CC.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.
